Top-News
Montag,
15.05.2017 14:05
von
PR Newswire
| Aufrufe: 32
Dynasil Corporation of America Reports Second Quarter Fiscal 2017 Gross Margin Improves 2%, Up to 38% from 36% in 2016
Mann mit Smartphone und Tablet (Symbolbild).
© metamorworks / iStock / Getty Images Plus / Getty Images
PR Newswire
NEWTON, Mass., May 15, 2017
NEWTON, Mass., May 15, 2017 /PRNewswire/ -- Dynasil Corporation of America (NASDAQ: DYSL), a developer and manufacturer of optics and photonics products, optical detection and analysis technology and components for the homeland security, medical and industrial markets, today announced continued success in its efforts to improve gross profit margin in the Company's operating segments.
"I am happy to report that both of our operating segments continued to be profitable both for the quarter and six months ended March 31, 2017, showing continued improvements in gross profit margin," said CEO Peter Sulick. "Our operating businesses are continuing to make strides in improving yields and productivity. For both the quarter and the six months, the Company realized a 2% overall improvement in margin despite an overall reduction in revenue from the prior year. The revenue reduction in these periods is the result of certain one-time revenue opportunities the Company was able to take advantage of in the first half of 2016, the effect of the devaluation in the British currency and a softening of revenue in project revenue at RMD. Despite this, the Company's profitability was roughly equivalent to the prior year before the reversal of the deferred tax valuation."
Certain key metrics by segment for the current quarter and the same period last year are presented below:
| Results of Operations for the Three Months Ended March 31, 2017 | ||||
| | Optics | Contract | Biomedical | Total |
| Revenue | $ 5,281,000 | $ 4,804,000 | $ - | $ 10,085,000 |
| Gross profit | 1,913,000 | 1,875,000 | - | 3,788,000 |
| GM % | 36% | 39% | - | 38% |
| Operating expenses | 1,597,000 | 1,802,000 | 392,000 | 3,791,000 |
| Operating income (loss) | $ 316,000 | $ 73,000 | $ (392,000) | $ (3,000) |
| | | | | |
| Results of Operations for the Three Months Ended March 31, 2016 | ||||
| | Optics | Contract | Biomedical | Total |
| Revenue | $ 6,428,000 | $ 4,868,000 | $ - | $ 11,296,000 |
| Gross profit | 2,208,000 | 1,870,000 | - | 4,078,000 |
| GM % | 34% | 38% | - | 36% |
| Operating expenses | 1,882,000 | 1,800,000 | 355,000 | 4,037,000 |
| Operating income (loss) | $ 326,000 | $ 70,000 | $ (355,000) | $ 41,000 |
"Our Optics segment revenue decreased $1.1 million in the second quarter of 2017 as compared to the same period last year. This decrease primarily resulted from initial system orders and a safety stock sale to a large U.K. customer in the second quarter of fiscal year 2016. The second quarter of fiscal year 2017 represented a more normalized shipping schedule for this customer," continued Mr. Sulick. "Our Contract Research segment revenue was essentially equal to that of the same three month period in 2016. The research revenue was somewhat lower, but offset in part by increased commercial product revenue for items originally developed by the research teams, including shipments of our CLYC scintillation crystals to Thermo Fisher Scientific for use in their RadEye SPRD-GN spectroscopic personal radiation detectors."
Dynasil's net income (loss) attributable to common stockholders was approximately ($0.1) million or ($0.00) per share for the quarter ended March 31, 2017 and approximately breakeven or ($0.00) per share for the quarter ended March 31, 2016.
Earnings attributable to common stockholders for the six months ended March 31, 2017 were $2.8 million or $0.16 per common share, largely as the result of a U.S. income tax benefit resulting from the deconsolidation for tax purposes of Xcede Technologies, Inc., the Company's tissue sealant technology development joint venture. Because of the previously discussed Xcede Technologies' transactions in November 2016, Dynasil's ownership percentage in Xcede decreased to less than 80% and Dynasil will no longer include Xcede in its consolidated federal tax return, which resulted in an income tax benefit in the amount of $2.7 million for the six months ended March 31, 2017.
Conference Call Information
Dynasil will host a conference call for investors and analysts at 5:00 p.m. ET today, Monday, May 15, 2017. The call will be hosted by Chairman, CEO and President Peter Sulick and Chief Financial Officer Robert Bowdring. Those who wish to listen to the conference call can go to the event page at or visit the Investor Information section of the Company's website at www.dynasil.com. The call also may be accessed by dialing (888) 346-2613 or (412) 902-4252. For interested individuals unable to join the live conference call, a webcast replay will be available on the Company's website for one year.
About Dynasil
Dynasil Corporation of America (NASDAQ: DYSL) develops and manufactures optics and photonics products, optical detection and analysis technology and components for the homeland security, medical and industrial markets. Combining world-class expertise in research and materials science with extensive experience in manufacturing and product development, Dynasil is commercializing products including dual-mode radiation detection solutions for Homeland Security and commercial applications and sensors for non-destructive testing. Dynasil has an impressive and growing portfolio of issued and pending U.S. patents. The Company is based in Newton, MA, with additional operations in MA, MN, NY, NJ and the United Kingdom. More information about the Company is available at www.dynasil.com.
Forward-Looking Statements
This press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements regarding future events and our future results are based on current expectations, estimates, forecasts, and projections and the beliefs and assumptions of our management, including, without limitation, our expectations regarding results of operations and the strength of our intellectual property portfolio. These forward-looking statements may be identified by the use of words such as "plans", "intends," "may," "could," "expect," "estimate," "anticipate," "continue" or similar terms, though not all forward-looking statements contain such words. Actual results of the future events described in such forward-looking statements could differ materially from those stated in such forward-looking statements due to a number of important factors, including without limitation, our ability to develop and commercialize our products, including obtaining regulatory approvals, the size and growth of the potential markets for our products and our ability to serve those markets, the rate and degree of market acceptance of any of our products, general economic conditions, costs and availability of raw materials and management information systems, our ability to obtain and maintain intellectual property protection for our products, Xcede's ability to produce preclinical data sufficient to enable it to initiate clinical studies of its resorbable hemostatic patch, clinical results of Xcede's programs which may not support further development, competition, the loss of key management and technical personnel, our ability to obtain timely payment of our invoices to governmental customers, litigation, the effect of governmental regulatory developments, the availability of financing sources, our ability to deleverage our balance sheet, our ability to identify and execute on acquisition opportunities and integrate such acquisitions into our business, and seasonality, as well as the uncertainties set forth in the Company's Annual Report on Form 10-K and from time to time in the Company's other filings with the Securities and Exchange Commission. The Company disclaims any intention or obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.
| Dynasil Corporation of America and Subsidiaries | | | |
| Consolidated Balance Sheets (Unaudited) | | | |
| | | | |
| ASSETS | March 31, 2017 | | September 30, 2016 |
| Current Assets | | | |
| Cash and cash equivalents | $ 2,299,000 | | $ 2,607,000 |
| Accounts receivable, net | 3,325,000 | | 3,502,000 |
| Costs in excess of billings and unbilled receivables | 880,000 | | 1,208,000 |
| Inventories, net of reserves | 3,965,000 | | 3,726,000 |
| Prepaid expenses and other current assets | 1,148,000 | | 1,078,000 |
| Total current assets | 11,617,000 | | 12,121,000 Werbung Mehr Nachrichten zur Dynasil Of America Aktie kostenlos abonnieren
E-Mail-Adresse
Bitte überprüfe deine die E-Mail-Adresse.
Benachrichtigungen von ARIVA.DE (Mit der Bestellung akzeptierst du die Datenschutzhinweise) -1  Vielen Dank, dass du dich für unseren Newsletter angemeldet hast. Du erhältst in Kürze eine E-Mail mit einem Aktivierungslink. Hinweis: ARIVA.DE veröffentlicht in dieser Rubrik Analysen, Kolumnen und Nachrichten aus verschiedenen Quellen. Die ARIVA.DE AG ist nicht verantwortlich für Inhalte, die erkennbar von Dritten in den „News“-Bereich dieser Webseite eingestellt worden sind, und macht sich diese nicht zu Eigen. Diese Inhalte sind insbesondere durch eine entsprechende „von“-Kennzeichnung unterhalb der Artikelüberschrift und/oder durch den Link „Um den vollständigen Artikel zu lesen, klicken Sie bitte hier.“ erkennbar; verantwortlich für diese Inhalte ist allein der genannte Dritte. Andere Nutzer interessierten sich auch für folgende News |
